11 citations
,
April 2023 in “Annals of General Psychiatry” This study found that males treated with serotonergic antidepressants had an increased risk of erectile dysfunction, with an adjusted odds ratio of 3.2, and the risk for post-SSRI sexual dysfunction was 0.46%, emphasizing the importance of informed consent due to these potential irreversible side effects.
November 2023 in “Frontiers in Neuroendocrinology” This study suggests that post-finasteride syndrome and post-SSRI sexual dysfunction share potential etiopathogenetic mechanisms involving brain modulators, neurotransmitters, and gut microbiota, although more research is needed to understand these conditions fully.
36 citations
,
January 2014 in “The Journal of Sexual Medicine” This study found that transdermal testosterone significantly increased the frequency of satisfactory sexual events in women experiencing SSRI/SNRI-related loss of libido, but did not improve overall sexual self-rating scores.
8 citations
,
October 2021 in “The international journal of risk and safety in medicine” This paper describes the development of diagnostic criteria for several enduring sexual dysfunction conditions following the use of certain medications, highlighting common sexual and non-sexual symptoms.
January 2016 in “SHILAP Revista de lepidopterología” This paper presents a case where alopecia was associated with the use of escitalopram and improved after switching to duloxetine, alongside a literature review of antidepressant-related alopecia.